ATE446303T1 - Agonisten und antagonisten von sphingosin-1- phosphatrezeptoren - Google Patents

Agonisten und antagonisten von sphingosin-1- phosphatrezeptoren

Info

Publication number: ATE446303T1
Authority: AT; Austria
Prior art keywords: sub; sphingosine; agonists; antagonists; alkenyl
Prior art date: 2001-01-30

Application number

AT02704296T

Other languages

English (en)

Inventor

Timothy Macdonald

Kevin Lynch

Original Assignee

Univ Virginia

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-30

Filing date

2002-01-30

Publication date

2009-11-15

2002-01-30 Application filed by Univ Virginia filed Critical Univ Virginia

2009-11-15 Application granted granted Critical

2009-11-15 Publication of ATE446303T1 publication Critical patent/ATE446303T1/de

Links

102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 title abstract 3
108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 title abstract 3
239000000556 agonist Substances 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
125000003342 alkenyl group Chemical group 0.000 abstract 2
125000000217 alkyl group Chemical group 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
TTZMPOZCBFTTPR-UHFFFAOYSA-N O=P1OCO1 Chemical class O=P1OCO1 TTZMPOZCBFTTPR-UHFFFAOYSA-N 0.000 abstract 1
DLWPEEDVEAHLHI-UHFFFAOYSA-N OP(O)=O.O=P1OCO1 Chemical compound OP(O)=O.O=P1OCO1 DLWPEEDVEAHLHI-UHFFFAOYSA-N 0.000 abstract 1
229910019142 PO4 Inorganic materials 0.000 abstract 1
125000002877 alkyl aryl group Chemical group 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
125000001072 heteroaryl group Chemical group 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
239000010452 phosphate Substances 0.000 abstract 1
125000003107 substituted aryl group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
- C07F9/65068—Five-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Virology (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Obesity (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Rheumatology (AREA)

AT02704296T 2001-01-30 2002-01-30 Agonisten und antagonisten von sphingosin-1- phosphatrezeptoren ATE446303T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US26492701P	2001-01-30	2001-01-30
US32781401P	2001-10-09	2001-10-09
PCT/US2002/002715 WO2002064616A2 (en)	2001-01-30	2002-01-30	Agonists and antagonists of sphingosine-1-phosphate receptors

Publications (1)

Publication Number	Publication Date
ATE446303T1 true ATE446303T1 (de)	2009-11-15

Family

ID=26950835

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02704296T ATE446303T1 (de)	2001-01-30	2002-01-30	Agonisten und antagonisten von sphingosin-1- phosphatrezeptoren

Country Status (8)

Country	Link
US (1)	US7064217B2 (de)
EP (1)	EP1383778B1 (de)
JP (1)	JP2004529100A (de)
AT (1)	ATE446303T1 (de)
AU (1)	AU2002237988B2 (de)
CA (1)	CA2437358A1 (de)
DE (1)	DE60234092D1 (de)
WO (1)	WO2002064616A2 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPWO2003020313A1 (ja) *	2001-09-04	2004-12-16	小野薬品工業株式会社	スフィンゴシン−１−リン酸受容体調節剤からなる呼吸器疾患治療剤
ITRM20010688A1 (it)	2001-11-21	2003-05-21	Univ Roma	Composti immunoregolatori.
RU2358717C2 (ru) *	2002-05-16	2009-06-20	Новартис Аг	Применение средств, связывающих edg-рецептор, в лечении ракового заболевания
GB0217152D0 (en)	2002-07-24	2002-09-04	Novartis Ag	Organic compounds
AU2003259296A1 (en) *	2002-07-30	2004-02-16	University Of Virginia Patent Foundation	Compounds active in spinigosine 1-phosphate signaling
JP4571497B2 (ja)	2002-09-19	2010-10-27	杏林製薬株式会社	アミノアルコール誘導体とその付加塩及び免疫抑制剤
DK1602660T3 (da) *	2003-02-18	2011-05-23	Kyorin Seiyaku Kk	Aminophosphonsyrederivater, additionssalte deraf og S1P-receptormodulatorer
EP1628967B1 (de) *	2003-05-19	2014-04-09	Irm Llc	Die immunreaktion unterdrückende verbindungen und zusammensetzungen
EP1481680A1 (de) *	2003-05-30	2004-12-01	Aventis Pharma Deutschland GmbH	Verwendung von S1P
WO2005041899A2 (en)	2003-11-03	2005-05-12	University Of Virginia Patent Foundation	Orally available sphingosine 1-phosphate receptor agonists and antagonists
GB0401332D0 (en) *	2004-01-21	2004-02-25	Novartis Ag	Organic compounds
CN101905023B (zh) *	2004-07-16	2012-07-11	杏林制药株式会社	有效的医药使用方法及与副作用发生的防御相关的方法
WO2006014816A2 (en) *	2004-07-27	2006-02-09	Merck & Co., Inc.	Canis sphingosine 1-phosphate receptor isoform 2
BRPI0514316A (pt) *	2004-08-13	2008-06-10	Praecis Pharm Inc	métodos e composições para modulação de atividade de receptor de esfingosina-1-fosfato (s1p)
US20060223866A1 (en) *	2004-08-13	2006-10-05	Praecis Pharmaceuticals, Inc.	Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
PL1806338T3 (pl) *	2004-10-12	2016-07-29	Kyorin Seiyaku Kk	Sposób wytwarzania chlorowodorku 2-amino-2-[2-[4-(3-benzyloksyfenylotio)-2-chlorofenyio]etylo]-1,3-propanodioiu i jego hydratów oraz produkty pośrednie w ich wytwarzaniu
CA2590748A1 (en) *	2004-12-06	2006-06-15	University Of Virginia Patent Foundation	Aryl amide sphingosine 1-phosphate analogs
CA2596990A1 (en)	2005-02-14	2006-08-24	University Of Virginia Patent Foundation	Sphingosine 1-phosphate agonists comprising cycloalkanes and 5 -membered heterocycles substituted by amino and phenyl groups
GB0513431D0 (en)	2005-06-30	2005-08-10	Kherion Technology Ltd	Prophylactic compositions and uses
SI1932522T1 (sl) *	2005-10-07	2012-08-31	Kyorin Seiyaku Kk	Terapevtsko sredstvo za jetrno bolezen, ki vsebuje 2-amino-1,3- propandiolni derivat kot aktivno sestavino
WO2007043568A1 (ja)	2005-10-12	2007-04-19	Toa Eiyo Ltd.	Ｓ１ｐ３受容体拮抗剤
US7919519B2 (en)	2005-11-23	2011-04-05	Epix Pharmaceuticals Inc.	S1P receptor modulating compounds and use thereof
CA2630714C (en) *	2005-11-23	2014-01-14	Epix Delaware, Inc.	S1p receptor modulating compounds and use thereof
KR20080086546A (ko) *	2006-01-27	2008-09-25	유니버시티 오브 버지니아 페이턴트 파운데이션	신경병증성 통증의 치료 방법
TWI389683B (zh) *	2006-02-06	2013-03-21	Kyorin Seiyaku Kk	A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
WO2007092638A1 (en) *	2006-02-09	2007-08-16	University Of Virginia Patent Foundation	Bicyclic sphingosine 1-phosphate analogs
WO2007109330A2 (en)	2006-03-21	2007-09-27	Epix Delaware, Inc.	S1p receptor modulating compounds
RU2430925C2 (ru)	2006-08-08	2011-10-10	Киорин Фармасьютикал Ко., Лтд.	Производное аминофосфата и модулятор рецептора s1p, содержащий его в качестве активного ингредиента
CA2659599C (en)	2006-08-08	2014-06-17	Kyorin Pharmaceutical Co., Ltd.	Amino alcohol derivative and immunosuppressive agent having same as an active ingredient
JP2010510250A (ja) *	2006-11-21	2010-04-02	ユニバーシティオブバージニアパテントファンデーション	スフィンゴシン＝１−燐酸受容体アゴニスト活性を有するヒドリンダンアナログ
JP2010510251A (ja) *	2006-11-21	2010-04-02	ユニバーシティオブバージニアパテントファンデーション	スフィンゴシン＝１−燐酸受容体活性を有するベンゾシクロヘプチルアナログ
AU2007323618A1 (en)	2006-11-21	2008-05-29	University Of Virginia Patent Foundation	Tetralin analogs having sphingosine 1-phosphate agonist activity
EP2142184B1 (de) *	2007-05-04	2018-10-24	Novartis AG	Verwendung des s1p-rezeptormodulators
CN101358609A (zh) *	2007-08-03	2009-02-04	富准精密工业(深圳)有限公司	风扇转子
ATE505454T1 (de)	2007-09-20	2011-04-15	Amgen Inc	1-(4-(4-benzylbenzamid)-benzyl)-azetidin-3- carboxylsäurederivate und entsprechende verbindungen als s1p-rezeptor-modulatoren zur behandlung von immunerkrankungen
WO2009085847A1 (en)	2008-01-03	2009-07-09	Allergan, Inc.	Tetrahydroindoles having sphingosine-1-phosphate receptor activity
JP5452237B2 (ja) *	2008-02-07	2014-03-26	杏林製薬株式会社	アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
US8212010B2 (en) *	2008-02-25	2012-07-03	Expression Drug Designs, Llc	Sphingosine 1-phosphate antagonism
CN104311472B9 (zh)	2008-07-23	2020-03-17	艾尼纳制药公司	经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物
AU2009282017B2 (en) *	2008-08-12	2014-08-07	Allergan, Inc.	Sphingosine-1-phosphate (S1P) receptor antagonists and methods for use thereof
PL2342205T4 (pl)	2008-08-27	2016-12-30		Podstawione tricykliczne pochodne kwasowe jako antagoniści receptora S1P1 użyteczni w leczeniu zaburzeń autoimmunologicznych i zapalnych
ES2466695T3 (es) *	2008-10-30	2014-06-11	Biogen Idec Ma Inc.	Análogos de esfingosina 1-fosfato de arilo bicíclico
EP2364089B1 (de) *	2008-10-30	2016-12-07	Biogen MA Inc.	Heterobicyclische sphingosin-1-phosphatanaloge
US9181191B2 (en)	2008-10-30	2015-11-10	Biogen Ma Inc.	Heterobicyclic sphingosine 1-phosphate analogs
WO2011028927A1 (en) *	2009-09-04	2011-03-10	Allergan, Inc.	Selective sphingosine-1-phosphate receptor antagonists
EP2528894A1 (de)	2010-01-27	2012-12-05	Arena Pharmaceuticals, Inc.	Verfahren zur herstellung von (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)essigsäure und salzen daraus
CN105503882B (zh)	2010-03-03	2019-07-05	艾尼纳制药公司	制备s1p1受体调节剂及其晶体形式的方法
US10106778B2 (en) *	2012-11-08	2018-10-23	Whitehead Institute For Biomedical Research	Selective targeting of cancer stem cells
US9771326B2 (en) *	2012-11-20	2017-09-26	Biogen Ma Inc.	S1P and/or ATX modulating agents
US10398672B2 (en)	2014-04-29	2019-09-03	Whitehead Institute For Biomedical Research	Methods and compositions for targeting cancer stem cells
CA3002540C (en)	2015-01-06	2023-11-07	Arena Pharmaceuticals, Inc.	Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
JP6838744B2 (ja)	2015-06-22	2021-03-03	アリーナファーマシューティカルズ，インコーポレイテッド	Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
KR20190113955A (ko)	2017-02-16	2019-10-08	아레나 파마슈티칼스, 인크.	장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법
CN110520124A (zh)	2017-02-16	2019-11-29	艾尼纳制药公司	用于治疗原发性胆汁性胆管炎的化合物和方法
IL252151A0 (en)	2017-05-07	2017-07-31	Fainzilber Michael	Treatment of stress disorders
JP7397011B2 (ja)	2018-06-06	2023-12-12	アリーナファーマシューティカルズ，インコーポレイテッド	Ｓ１ｐ１受容体に関連する状態を治療する方法
EP3847158B1 (de)	2018-09-06	2026-06-24	Arena Pharmaceuticals, Inc.	Verbindungen zur behandlung von autoimmun- und entzündungserkrankungen
EP4353266A4 (de)	2021-05-31	2026-04-29	Rena Therapeutics Inc	Ligandgebundener nukleinsäurekomplex

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2548155A (en) *	1948-10-02	1951-04-10	Goodrich Co B F	Preparation of amides
US3193458A (en) *	1961-07-12	1965-07-06	Us Vitamin Pharm Corp	Method of lowering blood cholesterol level
US4906767A (en)	1987-06-30	1990-03-06	The University Of Southern Mississippi	Monomers with urea groups
WO1990002727A1 (fr)	1988-09-14	1990-03-22	Yoshitomi Pharmaceutical Industries, Ltd.	Immunodepresseur
DE4134156A1 (de)	1991-10-11	1993-04-15	Schering Ag	9-substituierte bicyclo(3.3.0)octan-derivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
DE4225488A1 (de)	1992-07-30	1994-02-03	Schering Ag	Neue Bicyclo[3.3.0]octan-Derivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
KR0155015B1 (ko)	1992-10-21	1998-12-01	고우야 마사시	2-아미노-1,3-프로판디올 화합물 및 면역 억제제
IT1271267B (it)	1994-12-14	1997-05-27	Valle Francesco Della	Ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi
US5604988A (en) *	1995-03-30	1997-02-25	Costelloe; Paul M.	Multipurpose device for marking or placing a workpiece
US5773475A (en) *	1997-03-17	1998-06-30	Research Corporation Technologies, Inc.	Anticonvulsant enantiomeric amino acid derivatives
JP2000511173A (ja) *	1996-05-27	2000-08-29	藤沢薬品工業株式会社	一酸化窒素産生阻害剤としての新規なインドリルおよびベンゾフラニルカルボキサミド
ES2240868T3 (es)	1997-04-04	2005-10-16	Mitsubishi Pharma Corporation	Compuesto de 2-aminopropano -1,3-diol, su uso farmaceutico e intermedios en su sintesis.
WO1999012890A1 (fr) *	1997-09-11	1999-03-18	Takara Shuzo Co., Ltd.	Derives de sphingosine et composition medicamenteuse
SK287073B6 (sk) *	1998-06-30	2009-11-05	Om Pharma	N-Acyldipeptidový derivát, spôsob jeho prípravy a farmaceutický prostriedok, ktorý ho obsahuje
EP1195165A4 (de)	1999-07-12	2005-08-10	Ono Pharmaceutical Co	Fibrose inhibitore die als aktiven bestandteil sphingosin-a-phosphat oder dessen rezeptoragonisten enthalten
US6667163B2 (en)	2000-02-07	2003-12-23	Merck & Co., Inc.	Polynucleotide sequences encoding mouse sphingosine-1-phosphate phosphatase
ATE420878T1 (de)	2000-02-18	2009-01-15	Kyowa Hakko Kirin Co Ltd	Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente
CA2402038C (en)	2000-03-17	2011-03-15	The University Of Tennessee Research Corporation	Lpa receptor agonists and antagonists and methods of use
WO2001098301A1 (en)	2000-06-20	2001-12-27	Japan Tobacco Inc.	Pyrazolopyridine compounds and use thereof as drugs
CZ200350A3 (cs)	2000-07-13	2003-05-14	Sankyo Company Limited	Aminoalkoholové deriváty
WO2002018395A1 (en)	2000-08-31	2002-03-07	Merck & Co., Inc.	Phosphate derivatives as immunoregulatory agents
US20020072502A1 (en)	2000-09-01	2002-06-13	Neuronyx, Inc.	Novel synthetic gangliosides
EP1469863A2 (de)	2002-01-18	2004-10-27	Merck & Co., Inc.	Selektive s1p1/edg1-rezeptoragonisten

2002
- 2002-01-30 JP JP2002564545A patent/JP2004529100A/ja active Pending
- 2002-01-30 CA CA002437358A patent/CA2437358A1/en not_active Abandoned
- 2002-01-30 WO PCT/US2002/002715 patent/WO2002064616A2/en not_active Ceased
- 2002-01-30 AT AT02704296T patent/ATE446303T1/de not_active IP Right Cessation
- 2002-01-30 EP EP02704296A patent/EP1383778B1/de not_active Expired - Lifetime
- 2002-01-30 AU AU2002237988A patent/AU2002237988B2/en not_active Ceased
- 2002-01-30 DE DE60234092T patent/DE60234092D1/de not_active Expired - Fee Related
- 2002-01-30 US US10/470,820 patent/US7064217B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US7064217B2 (en)	2006-06-20
WO2002064616A2 (en)	2002-08-22
JP2004529100A (ja)	2004-09-24
DE60234092D1 (de)	2009-12-03
AU2002237988B2 (en)	2008-01-03
WO2002064616A3 (en)	2002-11-14
CA2437358A1 (en)	2002-08-22
EP1383778B1 (de)	2009-10-21
EP1383778A2 (de)	2004-01-28
US20040110728A1 (en)	2004-06-10
EP1383778A4 (de)	2005-03-09

Legal Events

Date	Code	Title	Description
2010-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60234092D1 (de)	2009-12-03	Agonisten und antagonisten von sphingosin-1-phosphatrezeptoren
ATE380187T1 (de)	2007-12-15	Agonisten und antagonisten für den lpa-rezeptor und anwendungsmethoden
MY147730A (en)	2013-01-15	Metabotropic glutamate receptor antagonists
DK1628685T3 (da)	2011-03-21	Antivirale phosphonatanaloge
WO2005002626A3 (en)	2005-05-26	Therapeutic phosphonate compounds
BRPI0409680A (pt)	2006-04-18	análogos de fosfonato anti-cáncer
ECSP045229A (es)	2004-09-28	Piridinonas sustituidas como moduladores de la p38 map quinasa
ATE363473T1 (de)	2007-06-15	Substituierte pyrazoloverbindungen zur behandlung von entzündungen
EA200600358A1 (ru)	2006-08-25	Фенил- или пиридиламидные соединения в качестве антагонистов простагландина е2
BE2013C003I2 (de)	2020-08-20
MXPA05010824A (es)	2005-12-05	Compuestos biciclicos como antagonistas del receptor nr2b.
TW200519096A (en)	2005-06-16	Quinazoline analogs as receptor tyrosine kinase inhibitors
BR0213094A (pt)	2004-10-13	Derivados de cromano como ligandos de 5-hidroxi-triptamina-6
DE602004027409D1 (de)	2010-07-08	Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation
EA200000336A1 (ru)	2000-10-30	Антагонисты рецептора витронектина
EA200301317A1 (ru)	2004-06-24	Производные аминохинолина и его применение в качестве лигандов аденозина a3
ES2167617T3 (es)	2002-05-16	Derivados de 1-bencenosulfonilpirrolidina como antagonistas del receptor de la bradiquinina.
ATE416174T1 (de)	2008-12-15	Substituierte homopiperidylbenzimidazolanaloga als fundusrelaxantien
BR0311970A (pt)	2005-03-29	Novos compostos, seu uso e preparação
BR9813920A (pt)	2000-09-26	Trifluorometilbifenilil-dihalofenilazolinas como pesticidas
EA200200733A1 (ru)	2002-12-26	Новые гетероарильные производные, их получение и применение
ATE314059T1 (de)	2006-01-15	VERWENDUNG VON ßXYLYLOXY ALKYL AMINESß FÜR DIE BEHANDLUNG VON TINNITUS
MXPA05011287A (es)	2006-01-24	Analogos de fosfonato anti-cancer.
BRPI0409677A (pt)	2006-04-18	análogos de fosfonato inibidores de cinase
NO20014126L (no)	2001-08-24	Ny fremgangsmåte for fremstilling av en benzotiazolonforbindelse